Table 5.

Clinical and quantitative complement assessment of patients with genetic variants in complement factor B

PatientDiagnosisGA (wk+d)Age (yr)PBMI (kg/m2)Plt (mm3 in 103)AST (IU/L)Cr (mg/dl)Urine PCGene (variant)Bb (μg/ml)aC5 (mg/dl)asMAC (ng/ml)a
5HELLP3131023.4622410.72.2CFB (p.L9H)1.327.2382.5
6HELLP26 + 421126442580.60.4CR1L (p.K88N)1.221.2235.9
CFB (p.L9H)
C3AR1 (p.L333P)
17Early PE33 + 226030.1201410.70.57CFB (p.G252S, p.E566A)1.228.6487.3
CFHR2 (p.T71M)
12Early PE31 + 4375331162310.97CFHR5 (p.R356H) CR1L (p.V5001) CFB (p.L9H)0.822.7199.9
14Early PE3433034238240.61041bCFB (p.L9H)0.528.9206.9
  • GA, gestational age; P, parity; BMI, body mass index; Plt, platelets; AST, aspartate aminotransferase; Cr, creatinine;

  • PC, protein-creatinine ratio; sMAC, soluble membrane attack complex; HELLP, hemolysis, elevated liver enzymes, and low platelets; early PE, early-onset preeclampsia with severe features.

  • a Reference ranges in nonpregnant cohort: Bb, ≤1.6 μg/ml; C5, 13–26.3 mg/dl; and sMAC, ≤250 ng/ml.

  • b 24-hour urine protein (in milligrams).